See more : Dyne Therapeutics, Inc. (DYN) Income Statement Analysis – Financial Results
Complete financial analysis of AB Science S.A. (AB.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AB Science S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Jiangxi Xinyu Guoke Technology Co., Ltd (300722.SZ) Income Statement Analysis – Financial Results
- Monopar Therapeutics Inc. (MNPR) Income Statement Analysis – Financial Results
- China Resources Power Holdings Company Limited (CRPJF) Income Statement Analysis – Financial Results
- Sasol Limited (SOL.JO) Income Statement Analysis – Financial Results
- National Plastic Industries Limited (NATPLAS.BO) Income Statement Analysis – Financial Results
AB Science S.A. (AB.PA)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ab-science.com
About AB Science S.A.
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 970.00K | 958.00K | 1.61M | 1.58M | 1.57M | 1.70M | 1.74M | 1.51M | 2.28M | 2.10M | 1.93M | 1.34M | 1.10M | 917.00K | 316.00K |
| Cost of Revenue | 383.00K | 31.00K | 111.00K | 69.00K | 181.00K | 248.00K | 121.00K | 453.00K | 339.00K | 394.00K | 331.00K | 238.00K | 301.00K | 377.00K | 150.00K |
| Gross Profit | 587.00K | 927.00K | 1.50M | 1.51M | 1.39M | 1.45M | 1.62M | 1.06M | 1.95M | 1.71M | 1.60M | 1.10M | 803.00K | 540.00K | 166.00K |
| Gross Profit Ratio | 60.52% | 96.76% | 93.09% | 95.64% | 88.48% | 85.42% | 93.04% | 69.96% | 85.16% | 81.23% | 82.88% | 82.24% | 72.74% | 58.89% | 52.53% |
| Research & Development | 10.48M | 13.35M | 11.23M | 12.84M | 15.58M | 26.93M | 26.73M | 27.86M | 23.71M | 13.37M | 12.12M | 8.73M | 7.59M | 7.99M | 5.83M |
| General & Administrative | 1.49M | 1.87M | 3.58M | 2.64M | 2.26M | 2.39M | 2.27M | 2.48M | 2.32M | 2.03M | 1.83M | 1.91M | 1.84M | 10.52M | 12.26M |
| Selling & Marketing | 355.00K | 288.00K | 493.00K | 781.00K | 1.02M | 1.08M | 1.02M | 928.00K | 1.88M | 1.51M | 1.43M | 1.08M | 1.09M | 1.46M | 988.00K |
| SG&A | 1.84M | 2.16M | 4.07M | 3.42M | 3.28M | 3.47M | 3.29M | 3.41M | 4.20M | 3.54M | 3.26M | 2.99M | 2.93M | 11.98M | 13.25M |
| Other Expenses | 0.00 | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00K | -5.83M |
| Operating Expenses | 14.02M | 16.87M | 15.30M | 16.26M | 18.86M | 30.40M | 30.02M | 31.26M | 27.91M | 16.91M | 15.37M | 11.71M | 10.52M | 11.71M | 13.25M |
| Cost & Expenses | 14.40M | 16.90M | 15.42M | 16.33M | 19.05M | 30.64M | 30.14M | 31.71M | 28.25M | 17.30M | 15.70M | 11.95M | 10.82M | 12.09M | 13.40M |
| Interest Income | 2.65M | 1.07M | 887.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 168.00K | 0.00 | 0.00 | 360.00K | 292.00K | 180.00K | 321.00K |
| Interest Expense | 3.96M | 2.02M | 1.29M | 117.00K | 17.00K | 0.00 | 0.00 | 474.00K | 1.21M | 1.00M | 747.00K | 653.00K | 257.00K | 77.00K | 128.00K |
| Depreciation & Amortization | 990.00K | 805.00K | 886.00K | 1.09M | 853.00K | 669.00K | 436.00K | 611.00K | 72.00K | -192.00K | 721.00K | 405.00K | 478.00K | 717.00K | 365.00K |
| EBITDA | -9.28M | -13.41M | -13.32M | -14.40M | -20.65M | -28.27M | -27.97M | -29.60M | -25.57M | -14.92M | -13.45M | -10.17M | -9.19M | -8.87M | -7.77M |
| EBITDA Ratio | -956.80% | -1,210.33% | -710.08% | -870.06% | -1,314.64% | -1,477.60% | -1,539.79% | -1,740.78% | -1,117.43% | -711.01% | -669.12% | -743.73% | -836.87% | -947.98% | -2,408.54% |
| Operating Income | -13.43M | -15.94M | -13.81M | -14.75M | -17.47M | -28.94M | -28.40M | -30.21M | -25.96M | -15.20M | -13.77M | -10.61M | -9.72M | -9.59M | -8.30M |
| Operating Income Ratio | -1,384.43% | -1,663.67% | -859.24% | -931.71% | -1,112.29% | -1,701.59% | -1,633.35% | -2,003.12% | -1,136.78% | -724.30% | -712.47% | -792.01% | -880.07% | -1,045.69% | -2,625.63% |
| Total Other Income/Expenses | 3.38M | 2.33M | -619.00K | -288.00K | -4.27M | 2.89M | 1.29M | 2.50M | -841.00K | -979.00K | -887.00K | -411.00K | 50.00K | 102.00K | 193.00K |
| Income Before Tax | -10.05M | -13.61M | -14.43M | -15.04M | -21.74M | -26.06M | -27.12M | -27.71M | -26.81M | -16.18M | -14.66M | -11.02M | -9.67M | -9.49M | -8.10M |
| Income Before Tax Ratio | -1,035.77% | -1,420.77% | -897.76% | -949.91% | -1,384.09% | -1,531.86% | -1,559.23% | -1,837.27% | -1,173.60% | -770.89% | -758.30% | -822.69% | -875.45% | -1,034.57% | -2,564.56% |
| Income Tax Expense | 1.00K | 4.00K | 36.00K | 8.00K | 4.00K | 4.00K | 6.00K | -11.00K | -88.00K | -70.00K | -48.00K | -39.00K | -15.00K | 2.00K | 6.00K |
| Net Income | -10.05M | -13.62M | -14.46M | -15.05M | -21.75M | -26.06M | -27.12M | -27.70M | -26.72M | -16.11M | -14.61M | -10.99M | -9.65M | -9.49M | -8.11M |
| Net Income Ratio | -1,035.88% | -1,421.19% | -900.00% | -950.41% | -1,384.34% | -1,532.10% | -1,559.63% | -1,836.60% | -1,169.70% | -767.60% | -755.87% | -819.78% | -874.18% | -1,034.79% | -2,566.46% |
| EPS | -0.20 | -0.29 | -0.30 | -0.34 | -0.55 | -0.69 | -0.75 | -0.78 | -0.78 | -0.49 | -0.45 | -0.34 | -0.31 | -0.32 | -0.28 |
| EPS Diluted | -0.15 | -0.29 | -0.30 | -0.34 | -0.55 | -0.69 | -0.75 | -0.78 | -0.78 | -0.49 | -0.45 | -0.34 | -0.31 | -0.32 | -0.28 |
| Weighted Avg Shares Out | 49.66M | 47.14M | 47.52M | 44.23M | 39.40M | 37.78M | 35.99M | 35.65M | 34.20M | 32.94M | 32.83M | 32.20M | 31.40M | 29.65M | 28.53M |
| Weighted Avg Shares Out (Dil) | 68.20M | 47.14M | 47.52M | 44.23M | 39.40M | 37.78M | 35.99M | 35.65M | 34.20M | 32.94M | 32.83M | 32.20M | 31.40M | 29.65M | 28.53M |
Source: https://incomestatements.info
Category: Stock Reports